Clinical Trial Update: Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26 [Phase 2]

View source ↗

Summary

Phase 2 study update evaluating antibody persistence and booster-dose response in individuals who received Menactra vaccination three years prior in study MTA26…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcemia

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcemia | Phase 2 | Status: COMPLETED | Results posted: 2016-02-15